Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low”

220 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 220 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT06680596
What this trial is testing

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Who this might be right for
Breast Cancer MetastaticBreast Cancer Stage IV
UNICANCER 80
Testing effectiveness (Phase 2)UnknownNCT04965519
What this trial is testing

RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Who this might be right for
Gynecological Malignancy
RemeGen Co., Ltd. 120
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Testing effectiveness (Phase 2)Study completedNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 56
Testing effectiveness (Phase 2)Looking for participantsNCT05297617
What this trial is testing

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

Who this might be right for
Breast Cancer
UNICANCER 696
Testing effectiveness (Phase 2)Looking for participantsNCT07380646
What this trial is testing

The Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer

Who this might be right for
LeucogenRibociclibNeutropenia (Low White Blood Cell Count)+1 more
Second Affiliated Hospital, Zhejiang University, School of Medicine 94
Testing effectiveness (Phase 2)Looking for participantsNCT07661927
What this trial is testing

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)
UNICANCER 700
Testing effectiveness (Phase 2)UnknownNCT06000033
What this trial is testing

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Hospital of Shandong University 35
Not applicableStudy completedNCT07211451
What this trial is testing

Axillary Nodal Burden in HER2+ and TNBC

Who this might be right for
Breast Cancer
Gangnam Severance Hospital 1,571
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07368543
What this trial is testing

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 216
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT07817082
What this trial is testing

Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer With Ultra-Low HER2 Expression
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableStudy completedNCT05754047
What this trial is testing

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

Who this might be right for
HER2 Low Breast Carcinoma
Mahdis Bayat 3,582
Testing effectiveness (Phase 2)UnknownNCT02829008
What this trial is testing

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
Chinese Academy of Medical Sciences 120
Testing effectiveness (Phase 2)Study completedNCT00095563
What this trial is testing

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Who this might be right for
High-grade Salivary Gland CarcinomaHigh-grade Salivary Gland Mucoepidermoid CarcinomaLow-grade Salivary Gland Carcinoma+7 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Ended earlyNCT00726180
What this trial is testing

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Michigan Rogel Cancer Center 1
Testing effectiveness (Phase 2)WithdrawnNCT05967286
What this trial is testing

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Not applicableLooking for participantsNCT06711055
What this trial is testing

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 285
Next Page